In vitro efficacy of combined treatment depends on the underlying mechanism of resistance in imatinib-resistant Bcr-Abl-positive cell lines.

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Blood

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1182/BLOOD-2003-04-1074PMID 12933582
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.

  2003cited by this paper
• Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib.

  2003cited by this paper
• Chronic myeloid leukemia--advances in biology and new approaches to treatment.

  2003cited by this paper
• MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models.

  2003cited by this paper
• Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation.

  2002cited by this paper
• Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.

  2002cited by this paper
• BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90.

  2002cited by this paper
• Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia.

  2002cited by this paper
• In vitro studies of the combination of imatinib mesylate (Gleevec) and arsenic trioxide (Trisenox) in chronic myelogenous leukemia.

  2002cited by this paper
• Activity of the Bcr-Abl kinase inhibitor PD180970 against clinically relevant Bcr-Abl isoforms that cause resistance to imatinib mesylate (Gleevec, STI571).

  2002cited by this paper
• Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro.

  2002cited by this paper
• Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336.

  2002cited by this paper
• Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy

  2002cited by this paper
• BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study.

  2002cited by this paper
• Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study.

  2002cited by this paper
• Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.

  2002cited by this paper
• Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification

  2001cited by this paper
• Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells

  2001cited by this paper
• Changes in DNA Methylation in Neoplasia: Pathophysiology and Therapeutic Implications

  2001cited by this paper
• Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.

  2001cited by this paper
• Co-treatment with As2O3 enhances selective cytotoxic effects of STI-571 against Bcr-Abl-positive acute leukemia cells

  2001cited by this paper
• Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.

  2001cited by this paper
• Arsenic induces apoptosis of multidrug-resistant human myeloid leukemia cells that express Bcr-Abl or overexpress MDR, MRP, Bcl-2, or Bcl-x(L).

  2000cited by this paper
• Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance.

  2000cited by this paper
• BCR-ABL mediates arsenic trioxide-induced apoptosis independently of its aberrant kinase activity.

  2000cited by this paper
• The molecular biology of chronic myeloid leukemia.

  2000cited by this paper
• Efficacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-abl-positive cells.

  2000cited by this paper
• Chronic Myelogenous Leukemia: Biology and Therapy

  1999cited by this paper
• Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer

  1999cited by this paper
• Chronic myelogenous leukemia in nonlymphoid blastic phase

  1999cited by this paper
• The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells.

  1997cited by this paper
• Pharmacological approach for optimization of the dose schedule of 5-Aza-2’-deoxycytidine (Decitabine) for the therapy of leukemia

  1997cited by this paper
• Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients.

  1997cited by this paper
• Shc phosphorylation in myeloid cells is regulated by granulocyte macrophage colony-stimulating factor, interleukin-3, and steel factor and is constitutively increased by p210BCR/ABL.

  1994cited by this paper
• Interleukin-3 and p210 BCR/ABL activate both unique and overlapping pathways of signal transduction in a factor-dependent myeloid cell line.

  1993cited by this paper
• Cytotoxic activity and mechanism of action of 5-Aza-2'-deoxycytidine in human CML cells.

  1993cited by this paper
• Chronic myelogenous leukemia: biology and therapy.

  1993cited by this paper
• Tyrosine phosphorylation of rasGAP and associated proteins in chronic myelogenous leukemia cell lines.

  1992cited by this paper
• Comparison of antineoplastic activity of cytosine arabinoside and 5-aza-2'-deoxycytidine against human leukemic cells of different phenotype.

  1990cited by this paper
• Selective growth response to IL‐3 of a human leukaemic cell line with megakaryoblastic features

  1988cited by this paper
• Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors.

  1984cited by this paper
• Demonstration of permanent factor-dependent multipotential (erythroid/neutrophil/basophil) hematopoietic progenitor cell lines.

  1983cited by this paper
• Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays.

  1983cited by this paper
• Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome.

  1975cited by this paper
• A New Consistent Chromosomal Abnormality in Chronic Myelogenous Leukaemia identified by Quinacrine Fluorescence and Giemsa Staining

  1973cited by this paper

• Phase I/II study of dasatinib in combination with decitabine in patients with accelerated or blast phase chronic myeloid leukemia

  2020cites this paper
• Potent antiproliferative effect of fatty‐acid derivative AIC‐47 on leukemic mice harboring BCR‐ABL mutation

  2019cites this paper
• Assays for tyrosine phosphorylation in human cells.

  2019cites this paper
• Aberrant DNA Methylation in Chronic Myeloid Leukemia: Cell Fate Control, Prognosis, and Therapeutic Response

  2018cites this paper
• To Cure or Not to Cure: Consequences of Immunological Interactions in CML Treatment

  2018cites this paper
• Reduced tyrosine kinase inhibitor dose is predicted to be as effective as standard dose in chronic myeloid leukemia: a simulation study based on phase III trial data

  2018cites this paper
• Autophagic degradation determines the fate of T315I-mutated BCR-ABL protein

  2018cites this paper
• Dasatinib and Azacitidine Followed by Haploidentical Stem Cell Transplant for Chronic Myeloid Leukemia with Evolving Myelodysplasia: A Case Report and Review of Treatment Options

  2017cites this paper
• Phase I/II study of low-dose azacytidine in patients with chronic myeloid leukemia who have minimal residual disease while receiving therapy with tyrosine kinase inhibitors

  2017cites this paper
• CYTOGENETIC ANALYSIS TO THE EFFECT OF CRUDE EXTRACTS OF TWO TYPES OF TRUFFLES ON LYMPHOCYTES OF LEUKEMIC

  2015cites this paper
• Reversal of microRNA-150 silencing disadvantages crizotinib-resistant NPM-ALK(+) cell growth.

  2015cites this paper
• Role of matriptase (ST14) in chronic myeloid leukaemia.

  2014cites this paper
• Arsenic Trioxide for Non Acute Promyelocytic Leukemia Hematological Malignancies: A New Frontier

  2014cites this paper
• Guggulsterone of Commiphora mukul resin reverses drug resistance in imatinib-resistant leukemic cells by inhibiting cyclooxygenase-2 and P-glycoprotein.

  2014cites this paper
• Methylation analysis of the DAPK1 gene in imatinib-resistant chronic myeloid leukemia patients

  2014cites this paper
• Methylation analysis of the DAPK 1 gene in imatinib ‐ resistant chronic myeloid leukemia patients

  2014cites this paper
• Chronic Myeloid Leukemia— What Else is there Beyond Protein Kinase Inhibitors?

  2014cites this paper
• Suppression of Survivin Induced by a BCR-ABL/JAK2/STAT3 Pathway Sensitizes Imatinib-Resistant CML Cells to Different Cytotoxic Drugs

  2013cites this paper
• Double-edged effects of arsenic compounds: anticancer and carcinogenic effects.

  2013cites this paper
• Coupling of small leucine-rich proteoglycans to hypoxic survival of a progenitor cell-like subpopulation in Rhesus Macaque intervertebral disc.

  2013cites this paper
• Anticancer efficacy of cisplatin and trichostatin A or 5-aza-2′-deoxycytidine on ovarian cancer

  2013cites this paper
• mutation-dependent and -independent imatinib resistance Adaphostin-induced oxidative stress overcomes BCR/ABL

  2013cites this paper
• cells and BCR-ABL oncoprotein Combined effects of As4S4 and imatinib on chronic myeloid leukemia

  2013cites this paper
• Wnt5a enhances the response of CML cells to Imatinib Mesylate through JNK activation and γ-catenin inhibition.

  2013cites this paper
• VEGF depletion enhances bcr-abl-specific sensitivity of arsenic trioxide in chronic myelogenous leukemia

  2013cites this paper
• Inhibition of small GTPase RalA regulates growth and arsenic-induced apoptosis in chronic myeloid leukemia (CML) cells.

  2012cites this paper
• Novel Agents In CML Therapy: Tyrosine Kinase Inhibitors and Beyond

  2012cites this paper
• Enhanced ABL-inhibitor-induced MAPK-activation in T315I-BCR-ABL-expressing cells: a potential mechanism of altered leukemogenicity

  2012cites this paper
• Anti-leukemic effects of gallic acid on human leukemia K562 cells: downregulation of COX-2, inhibition of BCR/ABL kinase and NF-κB inactivation.

  2012cites this paper
• Leukemianet Recommendations from an expert panel on behalf of the European Evolving concepts in the management of chronic myeloid leukemia.

  2011cites this paper
• Dual mTORC2/mTORC1 Targeting Results in Potent Suppressive Effects on Acute Myeloid Leukemia (AML) Progenitors

  2011cites this paper
• Synergic effect of 3′-azido-3′-deoxythymidine and arsenic trioxide in suppressing hepatoma cells

  2011cites this paper
• Combination therapy with arsenic trioxide for hematological malignancies.

  2010cites this paper
• Characterization of the small molecule kinase inhibitor SU11248 (Sunitinib/ SUTENT) in vitro and in vivo

  2010cites this paper
• Potent reducing effects of vitamin D3 on the frequency of apoptosis induced by arsenic trioxide in NB4 cell line.

  2010cites this paper
• Mécanismes de résistance aux inhibiteurs de tyrosine kinase sur le modèle de leucémie myéloïde chronique

  2009cites this paper
• Towards cure of CML: why we need to know more about CML stem cells?

  2009cites this paper
• Molecular and immunophenotypic features of chronic myeloid leukemia in an era of evolving therapeutic strategies

  2009cites this paper
• DNA methylation: its role in cancer development and therapy.

  2008cites this paper
• chronic myeloid leukemia apoptosis by imatinib mesylate combined with arsenic trioxide in Coordination of intrinsic, extrinsic, and endoplasmic reticulum-mediated

  2008cites this paper
• cells and BCR-ABL oncoprotein and imatinib on chronic myeloid leukemia 4 S 4 Combined effects of As

  2008cites this paper
• Novel agents in CML therapy: tyrosine kinase inhibitors and beyond.

  2008cites this paper
• Arsenic trioxide mechanisms of action – looking beyond acute promyelocytic leukemia

  2008cites this paper
• Imatinib-resistant K562 cells are more sensitive to celecoxib, a selective COX-2 inhibitor: role of COX-2 and MDR-1.

  2008cites this paper
• Optimizing outcomes for patients with advanced disease in chronic myelogenous leukemia.

  2008cites this paper
• Transcriptome and proteome analyses of drug interactions with natural products.

  2008cites this paper
• Enhanced Bcr-Abl-specific antileukemic activity of arsenic trioxide through glutathione-depletion in imatinib-resistant cells

  2007cites this paper
• Enhanced Bcr-Abl-specific antileukemic activity of arsenic trioxide (Trisenox) through glutathione-depletion in imatinib-resistant cells.

  2007cites this paper
• Chronic myeloid leukaemia.

  2007cites this paper
• A pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phase

  2007cites this paper
• Effect of Cytarabine and Decitabine in Combination in Human Leukemic Cell Lines

  2007cites this paper
• Rac guanosine triphosphatases represent integrating molecular therapeutic targets for BCR-ABL-induced myeloproliferative disease.

  2007cites this paper
• Phase II study of low‐dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia

  2007cites this paper
• Involvement of a Rho‐ROCK‐JNK pathway in arsenic trioxide‐induced apoptosis in chronic myelogenous leukemia cells

  2007cites this paper
• Mutant transcription factors and tyrosine kinases as therapeutic targets for leukemias: from acute promyelocytic leukemia to chronic myeloid leukemia and beyond.

  2007cites this paper
• Arsenical-based cancer drugs.

  2007cites this paper
• Signal Transduction Inhibitors in Chronic Myeloid Leukemia

  2007cites this paper
• Monitoring Disease Response

  2007cites this paper
• New Therapies for Chronic Myeloid Leukemia

  2007cites this paper
• Mechanisms of resistance to imatinib in CML patients: a paradigm for the advantages and pitfalls of molecularly targeted therapy.

  2006cites this paper
• In vitro dual effect of arsenic trioxide on hemopoiesis: inhibition of erythropoiesis and stimulation of megakaryocytic maturation.

  2006cites this paper
• BCR-ABL nuclear entrapment kills human CML cells: ex vivo study on 35 patients with the combination of imatinib mesylate and leptomycin B.

  2006cites this paper
• Overcoming drug resistance in chronic myeloid leukemia

  2006cites this paper
• Novel agents for chronic myeloid leukemia: From imatinib to dasatinib and nilotinib: Overcoming resistance

  2006cites this paper
• Antileukemic Activity of Lysophosphatidic Acid Acyltransferase-β Inhibitor CT32228 in Chronic Myelogenous Leukemia Sensitive and Resistant to Imatinib

  2006cites this paper
• Adaphostin-induced oxidative stress overcomes BCR/ABL mutation-dependent and -independent imatinib resistance.

  2006cites this paper
• Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.

  2006cites this paper
• Activation of mammalian target of rapamycin and the p70 S6 kinase by arsenic trioxide in BCR-ABL–expressing cells

  2006cites this paper
• A novel mechanism for BCR-ABL action: stimulated secretion of CCN3 is involved in growth and differentiation regulation.

  2006cites this paper
• Chronic myelogenous leukemia (CML): resistance to tyrosine kinase inhibitors.

  2006cites this paper
• Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML).

  2006cites this paper
• Mechanisms of Disease Persistence in Chronic Myelogenous Leukemia (CML)

  2006cites this paper
• New tyrosine kinase inhibitors in chronic myeloid leukemia.

  2005cites this paper
• Zoledronate inhibits proliferation and induces apoptosis of imatinib-resistant chronic myeloid leukaemia cells

  2005cites this paper
• New targeted approaches in chronic myeloid leukemia.

  2005cites this paper
• Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate.

  2005cites this paper
• Clinical development of decitabine as a prototype for an epigenetic drug program.

  2005cites this paper
• Arsenic in cancer therapy.

  2005cites this paper
• Synergistic Interactions between Imatinib and the Novel Phosphoinositide-Dependent Kinase-1 Inhibitor OSU-03012 in Overcoming Imatinib Resistance Running title : Overcome imatinib resistance by a PDK-1 inhibitor

  2005cites this paper
• Resistance to imatinib: mechanisms and management.

  2005cites this paper
• Cytokinetics and mechanism of action of AKO4: a novel nitrogen mustard targeted to bcr-abl.

  2005cites this paper
• Use of arsenic trioxide in haematological malignancies: insight into the clinical development of a novel agent

  2005cites this paper
• PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia.

  2005cites this paper
• CML clonal evolution with resistance to single agent imatinib therapy.

  2005cites this paper
• PDK-1/AKT pathway as targets for chemosensitizing effects.

  2005cites this paper
• Chronic Myeloid LeukemiaProgress in Hematology

  2005cites this paper
• ABERRANT EPIGENETICS IN THE MOLECULAR PATHOGENESIS OF HUMAN ACUTE MYELOID LEUKEMIA

  2005cites this paper
• Coordination of intrinsic, extrinsic, and endoplasmic reticulum-mediated apoptosis by imatinib mesylate combined with arsenic trioxide in chronic myeloid leukemia.

  2005cites this paper
• Synergistic interactions between imatinib mesylate and the novel phosphoinositide-dependent kinase-1 inhibitor OSU-03012 in overcoming imatinib mesylate resistance.

  2005cites this paper
• Kinase-addiction and bi-phasic sensitivity-resistance of Bcr-Abl- and Raf-1-expressing cells to imatinib and geldanamycin

  2005cites this paper
• Case study of primary imatinib resistance and correlation of BCR-ABL multiple mutations in chronic myeloid leukemia

  2004cites this paper
• The epigenetics of ovarian cancer drug resistance and resensitization.

  2004cites this paper
• Biology of Chronic Myeloid Leukemia and Possible Therapeutic Approaches to Imatinib-Resistant Disease

  2004cites this paper
• Imatinib Mesylate in the Treatment of Chronic Myelogenous Leukemia

  2004cites this paper
• Combined effects of As4S4 and imatinib on chronic myeloid leukemia cells and BCR-ABL oncoprotein.

  2004cites this paper
• Treatment of Chronic Myeloid Leukemia Cells with Imatinib (STI571) Impairs p53 Accumulation in Response to DNA Damage

  2004cites this paper
• Basic science going clinical: molecularly targeted therapy of chronic myelogenous leukemia

  2004cites this paper
• Investigational strategies in chronic myelogenous leukemia.

  2004cites this paper
• Autologous hematopoietic cell transplantation for chronic myelogenous leukemia.

  2004cites this paper
• Accelerated and blastic phases of chronic myelogenous leukemia.

  2004cites this paper